Drug Trial Radar · NCT07282054
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes
Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
550
Actual
Start
Apr 13, 2022
Primary completion
Jan 23, 2025
Study completion Jan 24, 2025
Sponsor
- Lead sponsor
- Tonghua Dongbao Pharmaceutical Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 26-week randomized, open-label, multicenter, active-controlled parallel group trial. The purpose of this study is to compare efficacy and safety of THDB0206 injection with insulin lispro injection combined with insulin glargine injection U-100 in Chinese participants with T1DM.
Conditions
- Type 1 Diabetes
Interventions
THDB0206Drug
Subcutaneous THDB0206 three times daily, with individualized dose adjustment.
Insulin LisproDrug
Subcutaneous insulin lispro three times daily, with individualized dose adjustment.
Insulin GlargineDrug
Subcutaneous insulin glargine once daily, with individualized dose adjustment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in HbA1c at Week 26Time frame: Week 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Drum Tower hospital
Nanjing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.